1Kitazono M, Takebayashi Y, Ishitsuka K, et al. Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase[J] . Biochem Biophys Res Commun, 1998,253: 797-803.
2Piccart M J, Goldhirsch A. The Breast International Group. An overview of recent and ongoing adjuvant clinical trials for breast cancer[M] .Brussels: Breast International Group,2000.
3Gokmen E,Karabulut B,Sezgin C,et al.A Phase Ⅱ Study of gemcitabine (G) and Vinorelbine(V) in patients with advanced breast cancer(ABC) [J]. Proc Annu Meet Am Soc Clin Oncol, 2000, 19: A427.
4Conte PF, Bengala C, Donato E, et al. Gemcitabine, epirubicin, and Taxol (GET) followed by high dose chemotherapy (HDCT): high activity with good tolerability in metastatic breast cancer patients[J] . Proc Annu Meet Am Soc Clin Oncol, 1999, 18:A449.
5Sobrevilla-Calvo P, Lara-Medina F, Martine-Magana J, et al. High dose (HD)gemcitabine (G)-paclitaxel (P)-cisplatin (C), with autologous peripheral blood stem cell transplantation (APBSCT) .A feasibility study of a novel conditioning regimen (COR) for breast cancer ( BC ) [ J ]. Proc Annu Meet Am Soc Clin Oncol, 1998, 17: A668.
6Early Breast Cancer Trialists Collaborative Group. Tanoxifen for early breast cancer: An overview of the randomised trids[J].lancet, 1998,351:1451-1467.
7Early Breast Cancer Trialists Collaborative Group. Polychemotherapy for early breast cancer: An overview of polychemotherapy for Early Breast Cancer Trialists' Collaborative Group[J]. Iancet, 1998, 352:930-942.
8Davidson NE. Hormonal ablation [A]. NIH. Consensus development conference on adjuvant therapy for breast cancer[C]. Bethesda: National Institutes of Health, 2000.63-66.
